Effect of Rituximab Injection combined with GDP chemotherapy on the efficacy and immune function of patients with non Hodgkin lymphoma
SHENG Weiwei1 SHAO Yu2▲
1.Department of Oncology, Taikang Xianlin Drum Tower Hospital of Nanjing City, Jiangsu Province, Nanjing 210000, China;
2.Department of Hematology, Yancheng Third People′s Hospital, Jiangsu Province, Yancheng 224000, China
Abstract:Objective To explore the effect of Rituximab Injection combined with GDP chemotherapy on the efficacy and immune function of patients with non Hodgkin lymphoma (NHL). Methods Ninety-three NHL patients admitted to Taikang Xianlin Drum Tower Hospital of Nanjing City in Jiangsu Province from May 2014 to December 2017 were selected as the research subjects. The patients were divided into control group (n = 46) and study group (n = 47) according to the random number table method. The control group was treated with the GDP chemotherapy regimen, and the study group was treated with Rituximab Injection on this basis. The clinical efficacy after treatment, immune function indexes [immunoglobulin (Ig) A, IgM, IgG and the body fluid complement C3, C4], tumor markers [thymine deoxy kinase (TK-1), vascular endothelial growth factor (VEGF)] before and after treatment were compared in the two groups. The adverse reactions of the two groups during treatment were observed. Results After treatment, the total effective rate of the study group was significantly higher than the control group (P < 0.05). IgA, IgM, IgG, C3, C4 of the two groups after treatment were lower than those before treatment, C3 and C4 of the study group were lower than those of the control group, the differences were statistically significant (P < 0.05); there was no significant difference in IgA, IgM, IgG between the two groups after treatment (P > 0.05). After treatment, TK-1 and VEGF of the two groups were lower than those before treatment, which of the study group were lower than those of the control group, the differences were statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P > 0.05). Conclusion Rituximab Injection combined with GDP chemotherapy in the treatment of NHL has a certain effect and can effectively protect the immune functions of the patients, significantly decrease the levels of serum TK-1 and VEGF, and does not increase the incidence of adverse reactions. It has certain clinical application value.
盛薇薇1 邵钰2▲. 利妥昔单抗注射液联合GDP化疗方案对非霍奇金淋巴瘤患者疗效及免疫功能的影响[J]. 中国医药导报, 2018, 15(35): 98-101.
SHENG Weiwei1 SHAO Yu2▲. Effect of Rituximab Injection combined with GDP chemotherapy on the efficacy and immune function of patients with non Hodgkin lymphoma. 中国医药导报, 2018, 15(35): 98-101.